Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
IONS insider filing for proposed sale of 60,846 shares. The filing shows a proposed disposition by Holly Kordasiewicz of 60,846 shares of Common Stock dated 06/12/2026 with an aggregate value of $4,466,425. The securities were originally granted as Restricted Stock on 01/15/2021.
IONS submitted a Form 144 notice dated 07/07/2026 reporting an intended sale of 67,386 shares of Common Stock on Nasdaq. The filing lists 20,536 as Owned Shares (01/15/2020) and 46,850 tied to a Stock Option Exercise (01/04/2021), with the broker noted as Stifel Nicolaus.
IONIS PHARMACEUTICALS INC director Michael J. Yang received equity awards as part of non-employee director compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units tied to common stock and 5,369 non-qualified stock options with an exercise price of $79.19 per share.
Both the RSUs and options vest 100% on the earlier of the first anniversary of grant or the next regularly scheduled annual stockholders’ meeting. The RSU delivery is deferred until the earlier of the fifth anniversary of vesting, a qualifying separation from service, or a change in control. After these grants, Yang directly holds 9,451 RSU-based common shares and 5,369 options. The company notes his 2026 annual equity compensation was adjusted to total no more than $400,000 in grant date fair value under its non-employee director policy.
IONIS PHARMACEUTICALS INC director Joseph Loscalzo received equity awards as part of non-employee director compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units, each representing one share of common stock or its cash equivalent, bringing his RSU-related holdings to 7,521 units.
He was also granted 5,369 Non-Qualified Stock Options with an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of grant or the next annual stockholders’ meeting, with RSUs delivered on the July 15 following vesting. The company’s Non-Employee Director Compensation Policy caps his 2026 annual equity compensation at $400,000 based on grant date fair value under FASB Topic ASC 718.
IONIS PHARMACEUTICALS INC director Joan E. Herman received new equity awards as part of non-employee director compensation. On July 1, 2026, Herman was granted 2,301 Restricted Stock Units, each representing a right to receive one share of Ionis common stock or its cash equivalent, subject to vesting.
On the same date, Herman was also granted options on 5,369 shares of common stock at an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, consistent with the company’s non-employee director compensation policy that caps 2026 equity compensation at $400,000 based on grant-date fair value.
Ionis Pharmaceuticals director Joseph Klein III reported multiple equity transactions in company stock. On July 1, 2026, he exercised options covering 11,518 shares of common stock at an exercise price of $39.94 per share and sold 11,518 shares in open-market transactions at weighted average prices around $79 per share pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025. He also received grants of 2,301 restricted stock units and 5,369 non-qualified stock options with a strike price of $79.19 per share under the company’s non-employee director compensation programs. A separate filing entry notes 200 shares held indirectly by his son, which he disclaims as beneficially owned.
IONIS PHARMACEUTICALS INC director equity awards: Non-employee director Michael R. Hayden received a grant of 2,301 Restricted Stock Units and 5,369 non-qualified stock options on July 1, 2026 as compensation. After the RSU grant, he holds 12,198 common-share equivalents directly.
The options have a $79.19 exercise price and both awards vest 100% on the earlier of the first anniversary of grant or the next annual stockholder meeting. Under the company’s non-employee director compensation policy, the 2026 equity awards were adjusted so Hayden’s total annual equity compensation does not exceed $400,000 based on grant date fair value.
Ionis Pharmaceuticals director Allene M. Diaz received equity awards as part of non-employee director compensation. On July 1, 2026, Diaz was granted 2,301 Restricted Stock Units and a Non-Qualified Stock Option for 5,369 shares of common stock at an exercise price of $79.19 per share.
The RSUs and options were granted under the company’s Amended and Restated 2002 Non-Employee Directors' Stock Option Plan and were adjusted so total 2026 equity compensation does not exceed $400,000 in grant date fair value under FASB Topic ASC 718. Both awards vest 100% on the earlier of the first anniversary of grant or the next annual stockholder meeting.
IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen received equity awards as non-cash compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units, each representing one share of Ionis common stock or its cash equivalent. These RSUs vest 100% on the earlier of the first anniversary of grant or the next regularly scheduled annual stockholder meeting, and will be delivered on the following July 15.
He was also granted 5,369 non-qualified stock options with an exercise price of $79.19 per share under the Amended and Restated 2002 Non-Employee Directors' Stock Option Plan, vesting 100% on the same schedule and not exercisable as of the grant date. Following the RSU grant, he holds 7,521 RSUs. The company states that, under its Non-Employee Director Compensation Policy, these grants were adjusted so that his 2026 annual equity compensation does not exceed $400,000 based on grant date fair value under FASB Topic ASC 718.